Navigation Links
XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
Date:3/26/2013

AUSTIN, Texas, March 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced the incorporation of its wholly owned Japanese subsidiary, XBiotech Japan KK. The creation of the Japanese Company is reportedly the first step in XBiotech's strategy to expand its clinical operations and ultimately product reach into the unique Japanese market place.

"XBiotech is committed to availing its drug development technologies to serve unmet medical need in Japan," said Erika Geimonen, Vice President of Business Development, XBiotech. "This is a very special market place and we look forward to working with the PMDA and our Japanese partners to help patients access important therapies. Whether we are talking about our True Human™ antibody therapies, or biosimilars, we offer the possibility of breakthrough with respect to how biological drugs can be used to help sustain Japanese patients and the Japanese healthcare system alike."

XBiotech's production technology is enabling unprecedented cost efficiencies. Making proprietary True Human™ biologics affordable will help enable access to new and larger markets, and promises to set a new bar for drug pricing. Yet, dramatic cost reductions for biosimilar drugs could be game changing—and permit very aggressive competition for market share for existing world-leading biological drug products. Hence, XBiotech has recently expanded its pipeline with the development of biosimilars.

About XBiotech
The Company has developed simple, minimal infrastructure production technology, dramatically reducing capital requirements and lead times, while greatly improving regulatory compliance and production flexibility. These processes are now a cornerstone of XBiotech's commercialization platform. The Company is now equipped with know how and technology to produce the most affordable biological drug products in the world—and to establish a new paradigm for cost efficiency in the biopharmaceutical industry.

At the heart of XBiotech is its pipeline of True Human™ monoclonal antibodies, the first of a new class of better, safer therapeutic antibodies. The use of the Company's lead True Human™ antibody in clinical programs to treat acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease have created anticipation for a single therapeutic agent capable of treating multiple diseases by blocking chronic inflammation. XBiotech believes that this extraordinary lead product represents what is perhaps the greatest single-product value potential in the history of therapeutic antibodies.

XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide. 
www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen
XBiotech
info@xbiotech.com
512.386.2906 


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. XBiotech Announces Positive Phase II Clinical Trial Results for Lead Candidate MABp1 in Acne Vulgaris
2. XBiotech Expands Portfolio to Include Biosimilars
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners has ... pioneering medical device for the treatment of Age-Related Macular Degeneration. , The company’s ... global regulatory consultancy that helps companies like ours secure government approvals for their ...
(Date:1/21/2017)... Colo. , Jan. 20, 2017 ... or the "Company"), announced that on January 14, 2017 ... plan under which the Company will terminate certain employees ... Bioptix Diagnostics, Inc.  The Company commenced terminations on January ... within 30 days.  The Company may pay severance benefits ...
(Date:1/21/2017)... , Jan. 21, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, today presented data ... napabucasin, at the 2017 American Society of Clinical Oncology ... . In a Phase Ib/II ... designed to inhibit cancer stemness pathways by targeting STAT3 ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
Breaking Biology Technology:
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... ... Research and Markets has announced the addition of the "Global ... The report forecasts the global military biometrics market to grow at a ... has been prepared based on an in-depth market analysis with inputs from ... over the coming years. The report also includes a discussion of the ...
Breaking Biology News(10 mins):